BLACU — Bellevue Life Sciences Acquisition Balance Sheet
0.000.00%
Last trade - 00:00FinancialsMicro Cap
- $60.22m
- $60.21m
Annual balance sheet for Bellevue Life Sciences Acquisition, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | PROSPECTUS/A | PROSPECTUS/A | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Cash | ||||
| Cash and Short Term Investments | 0.063 | 0.005 | 0.124 | 0.015 |
| Prepaid Expenses | ||||
| Total Current Assets | 0.063 | 0.005 | 0.124 | 0.023 |
| Long Term Investments | ||||
| Other Long Term Assets | ||||
| Total Assets | 0.323 | 0.705 | 1.23 | 36.6 |
| Payable / Accrued | ||||
| Accrued Expenses | ||||
| Notes Payable / Short Term Debt | ||||
| Total Other Current Liabilities | ||||
| Total Current Liabilities | 0.322 | 0.707 | 1.26 | 2.04 |
| Total Long Term Debt | ||||
| Total Debt | ||||
| Deferred Income Tax | ||||
| Total Liabilities | 0.322 | 0.707 | 1.26 | 4.11 |
| Common Stock | ||||
| Additional Paid In Capital | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| Total Equity | 0.001 | -0.002 | -0.038 | 32.5 |
| Total Liabilities & Shareholders' Equity | 0.323 | 0.705 | 1.23 | 36.6 |
| Total Common Shares Outstanding |